Statement of Financial Position [Abstract] Total current assets Total assets Total current liabilities Total liabilities Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Consolidated Statements of Loss and Comprehensive Loss [Abstract] Loss from operating activities Total other income, net Other segment income (expense) Loss before income tax benefit Net loss Net loss Consolidated Statements of Shareholders [Abstract] Balance (in Shares) Balance (in Shares) Shares outstanding (in Shares) Equity Components [Axis] Consolidated Statements of Cash Flows [Abstract] Net cash used in operating activities Net cash provided by investing activities Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Nature of Operations [Abstract] Summary of significant accounting policies [Abstract] Fair value measurements [Abstract] Cash and Cash Equivalents [Axis] Total liabilities Measurement Frequency [Axis] Fair Value Hierarchy and NAV [Axis] Equipment [Abstract] Long-Lived Tangible Asset [Axis] Net book value Intangible assets and goodwill [Abstract] Balance Balance IPR&D asset Indefinite-Lived Intangible Assets [Axis] Goodwill Goodwill Goodwill Trade and other payables [Abstract] Total trade and other payables Trade and other payables Stockholders’ equity [Abstract] Class of Warrant or Right [Axis] Beginning balance Ending balance Derivative warrant liabilities Derivative warrant liabilities (in Dollars) Measurement Input Type [Axis] Stock-based compensation [Abstract] Outstanding at end of period (in Shares) Outstanding at end of period (in Shares) Outstanding at end of period (in Dollars per share) Outstanding at end of period (in Dollars per share) Aggregate intrinsic value ending Aggregate intrinsic value ending Plan Name [Axis] Location, Statement of Income, Balance [Axis] Loss per share [Abstract] Antidilutive Securities [Axis] Income taxes [Abstract] Total Current Provision Total Deferred Provision Total Provision for Income Taxes Deferred income tax benefit Income tax benefit Income tax benefit Effective Tax Rate Effective tax rate Income Tax Jurisdiction [Axis] Total deferred income tax assets Total deferred income tax assets, net of valuation allowance Total deferred tax liabilities Segment Information [Abstract] Segments [Axis] Commitments and contingencies [Abstract] Subsequent Events [Abstract] Document Type Document Annual Report Current Fiscal Year End Date Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code Local Phone Number City Area Code Title of 12(b) Security Trading Symbol Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Document Financial Statement Error Correction [Flag] ICFR Auditor Attestation Flag Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Auditor Firm ID Auditor Name Auditor Location Entity Central Index Key Amendment Flag Document Fiscal Period Focus Current assets: Cash and cash equivalents Cash Receivables Prepaid expenses Equipment, net Intangible assets Current liabilities: Deferred tax liability Commitments and contingencies (Note 12) Stockholders’ equity: Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2026 and 2025 Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized (in shares) (in Shares) Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) (in Shares) Preferred shares, shares issued (in shares) Preferred stock, shares outstanding (in shares) (in Shares) Preferred shares, shares outstanding (in shares) Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,024,026 and 13,718,106 shares issued and outstanding as of March 31, 2026 and 2025, respectively Common stock, par value (in Dollars per share) Common shares, par value (in Dollars per share) Common stock, shares authorized (in shares) (in Shares) Common stock, shares authorized (in shares) Shares issued (in Shares) Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Operating expenses Research and development expenses Clinical development programs General and administrative expenses Foreign exchange loss Interest and other income, net Total comprehensive loss Basic loss per share (in Dollars per share) Diluted loss per share (in Dollars per share) Weighted average number of shares outstanding, basic (in Shares) Weighted average number of shares outstanding, diluted (in Shares) Stock-based compensation Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of pre-funded warrants (in Shares) Issuance of common stock upon exercise of common warrants Issuance of common stock upon exercise of common warrants (in Shares) Warrants exercised into common stock (in shares) Issuance of common stock upon cashless exercise of pre-funded warrants Issuance of common stock upon cashless exercise of pre-funded warrants (in Shares) Issuance of common stock and warrants through private placement, net of offering costs Issuance of common stock and warrants through private placement, net of offering costs (in Shares) Cash flows from operating activities: Adjustments: Depreciation expense Stock-based compensation Change in fair value of derivative warrant liabilities Change in fair value of derivative warrant liabilities Changes in operating assets and liabilities: Trade and other payables Cash flows from investing activities: Maturity of short-term investments Cash flows from financing activities: Gross proceeds from issuance of common stock and warrants from private placement Proceeds from issuance of common stock from common warrant exercise Proceeds from exercises of common warrants (in Dollars) Cash and cash equivalents are comprised of: Cash Cash equivalents Supplemental schedule of non-cash financing activities are comprised of: Issuance costs in accounts payable Settlement of derivative warrant liability Settlement of liability Settlement of derivative warrant liability (in Dollars) Loss on disposal Receivables Prepaid expenses Purchase of short-term investments Stock issuance costs Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss [Member] Accumulated Deficit [Member] Nature of operations Summary of significant accounting policies Fair value measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets Cash and cash equivalents Total assets Liabilities Equipment Summary of Equipment, Net Cost Intangible assets and goodwill Schedule of Impaired Intangible Assets